# Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy

> **NCT00442312** · PHASE4 · UNKNOWN · sponsor: **Genovate Biotechnology Co., Ltd.,** · enrollment: 43 (—)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** Combigan Ophthalmic Solutiom

## Key facts

- **NCT ID:** NCT00442312
- **Lead sponsor:** Genovate Biotechnology Co., Ltd.,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-05
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 43 (—)
- **Last updated:** 2007-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00442312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00442312, "Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT00442312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*